Geneious Prime Released With New Functionality for Streamlining Cloning WorkflowsThe Associated Press
AUCKLAND, New Zealand--(BUSINESS WIRE)--Nov 8, 2018--Biomatters is proud to announce the release of Geneious Prime 2019 today with a variety of features including significantly enhanced capability for primer design, an essential part of cloning operations in commercial organizations.
New primer design functionality includes more interactive display options, simplified testing and annotation, and many useability tweaks aimed at making cloning workflows more efficient.
“Primer design has always been a crucial tool for our customers,” says Head of Development Richard Moir. “We’ve focused on improving the experience of the user by taking the time to map out and understand their individual steps and the purpose behind them. Everything we’ve added has been considered from the point of a view of a biologist and aimed at creating more efficient processes.”
“As we continue to extend the core functionality of our flagship product, we get deeper involvement in the success of our biotech and pharma customers,” says Matt Cawte, Chief Commercial Officer. “The latest version of Geneious Prime integrates tightly with our Geneious Biologics offering, improving organizational workflow, analytics and data integrity in the drug discovery process.”
Geneious Prime forms part of the suite of solutions created for commercial organizations, including the rapidly developing biopharma sector.
About Geneious and Biomatters
Biomatters empowers its customers with software that transforms biological data into knowledge and actionable insights. Geneious solutions are created from a deep understanding of customer experience, and turn the difficult into the intuitive and easy. Geneious is trusted by over 4,000 companies, universities and institutes all over the globe.
View source version on businesswire.com:https://www.businesswire.com/news/home/20181108006002/en/
Melissa Pentecost, +64 21 258 1005
KEYWORD: AUSTRALIA/OCEANIA NEW ZEALAND
INDUSTRY KEYWORD: TECHNOLOGY DATA MANAGEMENT SOFTWARE HEALTH BIOTECHNOLOGY CLINICAL TRIALS GENETICS INFECTIOUS DISEASES PHARMACEUTICAL RESEARCH SCIENCE
Copyright Business Wire 2018.
PUB: 11/08/2018 04:28 PM/DISC: 11/08/2018 04:28 PM